Dr. Finn on New CDK 4/6 Inhibitors for Breast Cancer

Richard S. Finn, MD
Published Online: Monday, Aug 19, 2013

Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses new CDK 4/6 inhibitors for the treatment of breast cancer.

Other CDK inhibitors have been around a lot longer than palbociclib but have not broken out of the pack to show robust activity. Palbociclib, as a first-in-class CDK 4/6 inhibitor, has shown such benefit that there are now other CDK 4/6 inhibitors being developed.

These other drugs are in early phase and a ways behind, Finn says, so it remains to be seen how they can compete with palbociclib in the space.

Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses new CDK 4/6 inhibitors for the treatment of breast cancer.

Other CDK inhibitors have been around a lot longer than palbociclib but have not broken out of the pack to show robust activity. Palbociclib, as a first-in-class CDK 4/6 inhibitor, has shown such benefit that there are now other CDK 4/6 inhibitors being developed.

These other drugs are in early phase and a ways behind, Finn says, so it remains to be seen how they can compete with palbociclib in the space.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 20, 20162.5
Oncology Consultations®: Integrating Molecular Testing into the Breast Cancer Treatment ParadigmSep 28, 20162.0